Live data · NADAC + Part D CY24 · reviewed daily

Ergocalciferol (Vitamin D2)

Provitamin D2 Compound class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2018-12-10
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$20.2M in CY2024 Part D spend2.5M claims · 967K beneficiaries · 329 plans surveyed

Lowest NADAC
—/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
—
Across all dosage forms in distribution.
Highest NADAC
—
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Ergocalciferol (Vitamin D2) used for?

Ergocalciferol (Vitamin D2) is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Ergocalciferol (Vitamin D2)?

No. Ergocalciferol (Vitamin D2) is brand-only with no generic equivalents currently in market.

How much does my plan pay for Ergocalciferol (Vitamin D2)?

NADAC pricing data not currently available for this drug.

Is Ergocalciferol (Vitamin D2) on the FDA shortage list?

No. Ergocalciferol (Vitamin D2) is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.